ADAR1 Capital Management LLC Trims Holdings in Monopar Therapeutics Inc. $MNPR

Key Points

• ADAR1 Capital Management LLC reduced its stake in Monopar Therapeutics Inc. by 22.5%, now owning approximately $3.67 million worth of shares.
• Recent institutional activity includes JPMorgan Chase & Co. and Janus Henderson Group PLC establishing new positions in Monopar Therapeutics.
• Monopar's stock is currently trading at around $34.15, with a consensus price target of $66.00 and several analysts rating it as a "Moderate Buy."

ADAR1 Capital Management LLC cut its stake in Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) by 22.5% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 100,774 shares of the company's stock after selling 29,263 shares during the period. ADAR1 Capital Management LLC owned 1.65% of Monopar Therapeutics worth $3,669,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in MNPR. AlphaQuest LLC acquired a new stake in shares of Monopar Therapeutics during the first quarter worth $44,000. JPMorgan Chase & Co. acquired a new stake in Monopar Therapeutics in the fourth quarter worth $45,000. Gerber LLC acquired a new position in shares of Monopar Therapeutics during the first quarter valued at about $204,000. OMERS ADMINISTRATION Corp bought a new position in shares of Monopar Therapeutics during the 1st quarter worth about $328,000. Finally, Affinity Asset Advisors LLC acquired a new stake in shares of Monopar Therapeutics in the 1st quarter valued at about $2,257,000. Institutional investors own 1.83% of the company's stock.

Monopar Therapeutics Price Performance

Shares of NASDAQ MNPR traded up $5.37 during trading on Friday, hitting $44.21. The stock had a trading volume of 34,621 shares, compared to its average volume of 37,063. The firm has a fifty day moving average of $38.33 and a two-hundred day moving average of $36.60. The company has a market capitalization of $272.78 million, a PE ratio of -13.28 and a beta of 1.20. Monopar Therapeutics Inc. has a 12 month low of $2.29 and a 12 month high of $54.30.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last announced its earnings results on Tuesday, August 12th. The company reported ($0.35) earnings per share for the quarter, topping analysts' consensus estimates of ($0.47) by $0.12. On average, equities analysts expect that Monopar Therapeutics Inc. will post -1.65 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

MNPR has been the topic of several recent research reports. Cantor Fitzgerald reiterated an "overweight" rating and issued a $74.00 price target on shares of Monopar Therapeutics in a report on Wednesday, August 27th. Oppenheimer initiated coverage on Monopar Therapeutics in a report on Wednesday. They issued an "outperform" rating and a $77.00 target price on the stock. Chardan Capital restated a "buy" rating and set a $60.00 price target on shares of Monopar Therapeutics in a research note on Wednesday, August 13th. Wall Street Zen raised shares of Monopar Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. Finally, Raymond James Financial started coverage on shares of Monopar Therapeutics in a report on Tuesday. They set a "strong-buy" rating and a $80.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Hold rating to the company. According to MarketBeat, Monopar Therapeutics currently has an average rating of "Buy" and a consensus target price of $69.57.

Insider Buying and Selling

In related news, Director Christopher M. Starr sold 16,800 shares of the company's stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $40.00, for a total value of $672,000.00. Following the transaction, the director owned 5,173 shares in the company, valued at approximately $206,920. This represents a 76.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Kim R. Tsuchimoto sold 8,904 shares of the firm's stock in a transaction on Monday, July 14th. The stock was sold at an average price of $40.00, for a total value of $356,160.00. Following the completion of the sale, the director directly owned 11,486 shares of the company's stock, valued at $459,440. This represents a 43.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 42,504 shares of company stock valued at $1,700,160. 20.50% of the stock is owned by company insiders.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.